Cargando…
P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429241/ http://dx.doi.org/10.1097/01.HS9.0000968744.85748.62 |
| _version_ | 1785090662279938048 |
|---|---|
| author | Lopes De Menezes, Daniel Roboz, Gail Döhner, Hartmut Wei, Andrew Teresa Voso, Maria Schuh, Andre See, Wendy L. Ugidos, Manuel Amzallag, Arnaud Risueño, Alberto H. Eng, Kevin Nvs Suragani, Rajasekhar Skikne, Barry Beach, CL Prebet, Thomas Gandhi, Anita |
| author_facet | Lopes De Menezes, Daniel Roboz, Gail Döhner, Hartmut Wei, Andrew Teresa Voso, Maria Schuh, Andre See, Wendy L. Ugidos, Manuel Amzallag, Arnaud Risueño, Alberto H. Eng, Kevin Nvs Suragani, Rajasekhar Skikne, Barry Beach, CL Prebet, Thomas Gandhi, Anita |
| author_sort | Lopes De Menezes, Daniel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429241 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104292412023-08-17 P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS Lopes De Menezes, Daniel Roboz, Gail Döhner, Hartmut Wei, Andrew Teresa Voso, Maria Schuh, Andre See, Wendy L. Ugidos, Manuel Amzallag, Arnaud Risueño, Alberto H. Eng, Kevin Nvs Suragani, Rajasekhar Skikne, Barry Beach, CL Prebet, Thomas Gandhi, Anita Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429241/ http://dx.doi.org/10.1097/01.HS9.0000968744.85748.62 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Lopes De Menezes, Daniel Roboz, Gail Döhner, Hartmut Wei, Andrew Teresa Voso, Maria Schuh, Andre See, Wendy L. Ugidos, Manuel Amzallag, Arnaud Risueño, Alberto H. Eng, Kevin Nvs Suragani, Rajasekhar Skikne, Barry Beach, CL Prebet, Thomas Gandhi, Anita P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title | P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title_full | P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title_fullStr | P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title_full_unstemmed | P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title_short | P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS |
| title_sort | p459: disease monitoring of npm1-mutant (mut) acute myeloid leukemia (aml) using measurable residual disease (mrd) assessments during oral azacitidine (oral-aza) treatment (tx): a quazar aml-001 subanalysis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429241/ http://dx.doi.org/10.1097/01.HS9.0000968744.85748.62 |
| work_keys_str_mv | AT lopesdemenezesdaniel p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT robozgail p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT dohnerhartmut p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT weiandrew p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT teresavosomaria p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT schuhandre p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT seewendyl p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT ugidosmanuel p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT amzallagarnaud p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT risuenoalberto p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT hengkevin p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT nvssuraganirajasekhar p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT skiknebarry p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT beachcl p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT prebetthomas p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis AT gandhianita p459diseasemonitoringofnpm1mutantmutacutemyeloidleukemiaamlusingmeasurableresidualdiseasemrdassessmentsduringoralazacitidineoralazatreatmenttxaquazaraml001subanalysis |